Pancreas Cancer Clinical Trials

98 recruitingLast updated: July 16, 2026

There are 98 actively recruiting pancreas cancer clinical trials across 25 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Pancreas Cancer Trials at a Glance

98 actively recruiting trials for pancreas cancer are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 1 with 28 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running pancreas cancer studies include Minia University, Chongqing Precision Biotech Co., Ltd, and Second Affiliated Hospital of Guangzhou Medical University.

Browse pancreas cancer trials by phase

Treatments under study

About Pancreas Cancer Clinical Trials

Looking for clinical trials for Pancreas Cancer? There are currently 95 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreas Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreas Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 98 trials

Recruiting

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

Pancreas CancerHereditary Pancreatic CancerPancreatic Neoplasms+7 more
Università Vita-Salute San Raffaele600 enrolled1 locationNCT07700992
Recruiting
Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Breast CancerLiver CancerColorectal, Cancer+19 more
University of California, Irvine75 enrolled1 locationNCT06580002
Recruiting
Phase 1Phase 2

SL-28 for Advanced Solid Tumours

Breast CancerLiver CancerColorectal, Cancer+15 more
Second Life Therapeutics60 enrolled1 locationNCT07341737
Recruiting

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Pancreatic CancerPancreas Cancer
Memorial Sloan Kettering Cancer Center79 enrolled7 locationsNCT07612046
Recruiting
Not Applicable

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Pancreatic CancerPancreas CancerAdenocarcinoma of the Pancreas+1 more
HistoSonics, Inc.50 enrolled1 locationNCT06282809
Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting
Not Applicable

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

Pancreas CancerPancreas AdenocarcinomaPancreatic Fistula+4 more
Minia University100 enrolled1 locationNCT07022015
Recruiting

Pancreatic Cancer Early Detection Consortium

Pancreatic Ductal AdenocarcinomaPancreas CancerGenetic Predisposition+1 more
Arbor Research Collaborative for Health20,000 enrolled60 locationsNCT04970056
Recruiting

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

Pancreas Cancer
Northwestern University500 enrolled3 locationsNCT04616131
Recruiting
Phase 1Phase 2

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Pancreatic CancerPancreas Cancer
University of Virginia23 enrolled1 locationNCT06479239
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Breast CancerColorectal, CancerProstate Cancer+9 more
University Health Network, Toronto500 enrolled3 locationsNCT05403177
Recruiting
Phase 1

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Pancreas CancerRelapseResistant Cancer
UNC Lineberger Comprehensive Cancer Center27 enrolled1 locationNCT06158139
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Not Applicable

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Liver CancerEsophageal CancerColon Cancer+7 more
Case Comprehensive Cancer Center200 enrolled1 locationNCT06263088
Recruiting
Phase 3

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Pancreas CancerOligometastatic
M.D. Anderson Cancer Center80 enrolled3 locationsNCT06593431
Recruiting
Not Applicable

Promoting CT Engagement for Pancreatic Cancer With App

Pancreas Cancer
UNC Lineberger Comprehensive Cancer Center26 enrolled2 locationsNCT06252545
Recruiting
Not Applicable

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer

Breast CancerColon CancerPancreas Cancer+3 more
Gustave Roussy, Cancer Campus, Grand Paris170 enrolled3 locationsNCT07436312
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 2

Axelopran for Advanced Cancer in Patients Receiving Opioids

Breast CancerProstate CancerLung Cancer+1 more
HealthPartners Institute34 enrolled2 locationsNCT07354919